Idiopathic Pulmonary Fibrosis Epidemiology Overview and Insights 2018-2024 - ResearchAndMarkets.com

DUBLIN--()--The "Idiopathic Pulmonary Fibrosis: Epidemiology Overview and Insights" report has been added to ResearchAndMarkets.com's offering.

Idiopathic Pulmonary Fibrosis: Epidemiology Overview and Insights report delivers an in-depth understanding of the disease and the historical & forecasted epidemiology of Idiopathic Pulmonary Fibrosis disease in terms of diagnosed prevalent and the treated patients in the US, EU5 (Germany, France, Italy, Spain, UK), and Japan market till 2024. The epidemiology numbers in the report have been derived based on numerous studies, survey reports and views of key opinion leaders.

Disease Indication Overview:

This section of the report gives the overview of Idiopathic Pulmonary Fibrosis disease indication in detail. The section highlights the basic definition, causes and symptoms of disease and further details the types of Idiopathic Pulmonary Fibrosis disease. Further details on the profile of Idiopathic Pulmonary Fibrosis patients, Symptoms experienced by the patients, and disease progression in patients are outlined in the report. The report further highlights the multiple methods through which the patient can be diagnosed for Idiopathic Pulmonary Fibrosis disease.

Epidemiology Forecasts to 2024:

This section of the report provides the overview of Idiopathic Pulmonary Fibrosis diagnosed prevalent and treated patients in the US, EU5 (Germany, France, Italy, Spain and UK) and Japan market year wise starting from 2015 till 2024. The epidemiology numbers in the report have been derived based on numerous studies, survey reports and views of key opinion leaders.

Key Topics Covered:

1 Tables & Figures

2 Executive Summary

2.1 Key Metrics

3 Disease Overview

3.1 Disease Definition

3.2 Disease Etiology and Pathophysiology

3.2.1 Etiology

3.2.2 Pathophysiology

3.2.3 Impact on Quality of Life

3.3 Symptoms of the Disease

3.4 Disease Diagnosis

3.5 Treatment Guidelines

3.6 Key unmet needs

4 Disease Epidemiology

4.1 Diagnosed Prevalent Patient projections by Country (Forecast till 2024)

4.2 Treated Patient projections by Country (Forecast till 2024)

5 Appendix

Companies Mentioned

  • Boehringer Ingelheim
  • InterMune
  • Roche
  • Shionogi
  • GNI
  • Pharmathen
  • Ildong Pharmaceutical
  • Marnac
  • AFT Pharmaceuticals
  • Bristol-Myers Squibb
  • Medarex
  • FibroGen
  • Kyorin Holdings
  • MediciNova
  • Galapagos
  • Chugai Pharmaceutical
  • Afferent Pharmaceuticals
  • Merck & Co
  • Galecto Biotech
  • ProMetic Life Sciences
  • Promedior

For more information about this report visit https://www.researchandmarkets.com/research/bhggsw/idiopathic?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs